Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
Dabogratinib, an oral therapy for intermediate-risk NMIBC, posted 64% CR and 100% ORR in single marker lesions in phase II. Company says robust efficacy and safety support phase III advancement.
SURF302 interim results for intermediate-risk NMIBC show oral dabogratinib 60 mg with 79% ORR and 64% CR, described as well-tolerated for chronic dosing. The 60 mg dose is advancing to Phase III.
SURF302 initial results for oral dabogratinib 60 mg in intermediate-risk NMIBC report 79% ORR and 64% CR, with favorable safety, especially in single marker lesion patients, advancing to Phase III.